Following Ashitaba treatment, some key pathways were altered during the development of NAFLD, such as FXR/RXR (20), NF-κB (21), AMPK (22), and PPAR (23) (Figure 5A). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.